HoldsUp

Mark Hyman, MD · 2025-07-23 · Mark Hyman (host), Eric Topol

Alzheimer's Starts 20 Years Before You Notice It — Here's What to Do Now

56 research-tied claims examined: 2 contradicted 9 overstated 3 context 36 supported 6 unverified

2

Contradicted by research

0:32:13Mark Hyman (host)contradictedmoderate

Diets with high protein intake, particularly from animal sources, promote atherosclerosis and induce systemic inflammation.

"we've seen studies after study that show too high a protein diet, particularly animal protein, can induce, promote atherosclerosis. That's the last thing we want, right? It's pro-inflammatory." (said at 0:32:13)

Comprehensive systematic reviews and meta-analyses of prospective cohort studies and randomized controlled trials do not support the claim that high protein intake or animal protein promotes atherosclerosis or increases cardiovascular disease (CVD) risk. An umbrella review published by the German Nutrition Society found probable evidence for an absence of association between total, animal, or plant protein intake and coronary heart disease (CHD). Similarly, large meta-analyses of prospective cohorts found no significant association between total or animal protein intake and risk of CHD, hypertension, or cardiovascular mortality. In randomized trials, higher protein diets have been associated with improvements in blood pressure and vascular endothelial function (flow-mediated dilation).

0:43:55Eric Topolcontradictedhigh

On the Horvath epigenetic clock, the only two interventions demonstrated to decrease biological aging are exercise and GLP-1 receptor agonist drugs.

"Steve Horvath, who had came up with the Horvath clock, we were talking about that epigenetic— The only two things so far— —that have decreased biologic aging from that clock are exercise and then more recently the GLP-1 drugs." (said at 0:43:55)

The claim that exercise and GLP-1 receptor agonists are the only two interventions shown to reduce biological age on the Horvath epigenetic clock is contradicted by published interventional studies, including studies co-authored by Steve Horvath himself. The TRIIM trial (Fahy et al., 2019) demonstrated a mean 1.5-year reversal of epigenetic age using a cocktail of recombinant human growth hormone, DHEA, and metformin evaluated on the Horvath clock along with three other DNA methylation clocks. Additionally, randomized controlled pilot trials evaluating multimodal dietary and lifestyle modifications (e.g., Fitzgerald et al., 2021) and studies on ketogenic dietary interventions (e.g., Crujeiras et al., 2025) have reported significant reductions in Horvath DNAmAge. Systematic reviews of epigenetic age modifying interventions also document multiple lifestyle, dietary, and pharmacological strategies beyond exercise and GLP-1 agonists that lower biological age across various epigenetic clocks.

9

Overstated

0:00:06Eric Topoloverstatedmoderate

Plasma p-tau217 levels begin to rise 20 years before the onset of mild cognitive impairment.

"p-tau217 is the very first one that goes up and it starts 20 years before mild cognitive impairment. 20 years." (said at 0:00:06)

The speaker bundles two claims: that plasma p-tau217 is the 'very first' biomarker to change, and that it rises approximately 20 years before the onset of mild cognitive impairment (MCI). Longitudinal cohort data, such as a 25-year follow-up from the Women's Health Initiative Memory Study (PMID: 41805953), confirm that elevated baseline plasma p-tau217 levels are significantly associated with incident MCI and dementia up to 20 to 25 years before clinical manifestation. However, p-tau217 is not the 'very first' biomarker to become abnormal along the Alzheimer's disease continuum; trajectory modeling demonstrates that reductions in the plasma Aβ42/Aβ40 ratio precede increases in plasma phosphorylated tau species (PMID: 40539416).

0:22:45Eric Topoloverstatedmoderate

Blood-based p-tau217 testing performs as accurately as cerebrospinal fluid analysis and PET tau neuroimaging for Alzheimer's biomarker detection.

"because it's as good as a cerebrospinal fluid, it's as good as a PET tau scan, you know, which is a lot of radiation and hard to get" (said at 0:22:45)

While blood-based phosphorylated tau 217 (p-tau217) is an accurate biomarker for identifying Alzheimer's disease pathology (amyloid-beta positivity) and approaches the diagnostic accuracy of cerebrospinal fluid (CSF) testing in clinical screening, asserting that it is universally 'as good as a PET tau scan' is overstated. Cohort studies demonstrate that plasma p-tau217 assays primarily reflect early soluble tau phosphorylation in response to amyloid rather than the anatomical distribution or severity of insoluble neurofibrillary tangle pathology. For differentiating late-stage tau accumulation (A+T+ from A+T-), the accuracy of plasma p-tau217 assays decreases significantly (AUC 0.69–0.77), where tau-PET imaging remains the standard for staging.

0:27:10Eric Topoloverstatedhigh

In clinical trials, diabetic patients on GLP-1 drugs only lose 3 to 4 pounds on average, whereas non-diabetic individuals with obesity lose 40 to 80 pounds.

"And they kept saying to her, 'Well, Lotte, it's not going to work because the diabet- the diabetics only lose three or four pounds.' Well, now we see they we can get people to lose, you know, 40, 50, 60, 80 pounds. These drugs are so potent, and the reason we we it was blown was because the diabetics don't lose that weight" (said at 0:27:10)

While clinical trials consistently show that patients with type 2 diabetes experience somewhat less weight loss on GLP-1 receptor agonists than individuals without diabetes, the claimed disparity (3–4 pounds vs. 40–80 pounds) is a substantial exaggeration. In Phase 3 randomized trials of semaglutide 2.4 mg, adults with type 2 diabetes achieved an average weight loss of approximately 9.6% to 10% (around 20–22 pounds, as in the STEP 2 trial), far exceeding 3 to 4 pounds. Meanwhile, non-diabetic adults with overweight or obesity average approximately 15% to 17% weight loss (about 33–37 pounds across STEP 1, 3, and 5), rather than an average loss of 40 to 80 pounds.

0:18:59Mark Hyman (host)overstatedmoderate

On average, humans spend the last 20% of their lives in poor health or living with disease.

"we spend the last 20% of our lives in poor health that mean you do what you want and you're engaged and you feel good right and what's the point of living a long life if you feel like crap for the last 20% of your life" (said at 0:18:59)

The speaker overstates both the proportion of life spent in poor health and how that morbidity is distributed across a lifespan. Comprehensive data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD 2023) indicates that globally, individuals spend an average of 14.5% of their lives in poor health (a morbidity gap of approximately 10.7 years relative to total life expectancy), rather than 20%. In addition, demographic analyses demonstrate that health loss and disability accumulate across the adult life course rather than being strictly concentrated in the final years of life.

0:30:44Eric Topoloverstatedmoderate

The United States has the highest consumption of ultra-processed food in the world, with average consumption exceeding 70% of total diet and many individuals consuming 80% or more.

"and the US has the highest consumption in the world, 70% plus. And of course, a lot of people are 80% or more." (said at 0:30:44)

While systematic reviews confirm that the United States and the United Kingdom have the highest ultra-processed food (UPF) consumption rates internationally (generally exceeding 50% of total caloric intake), the speaker substantially overstates average US intake levels. Nationally representative data from NHANES show that the average contribution of UPFs to total energy intake is approximately 53% among adults and 62% among youth (overall average near 57–60%), well below the claimed average of '70% plus'.

0:53:25Eric Topoloverstatedmoderate

GLP-1 receptor agonists reduce cardiovascular inflammation prior to weight loss and prevent heart failure with preserved ejection fraction (HFpEF).

"We've already seen how GLP-1 drugs do that before any weight loss. So that should work well in people who aren't even obese, and we've seen how that can prevent heart—preserve ejection fraction heart failure, which is half of all heart failure, right? GLP-1s prevent that." (said at 0:53:25)

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, demonstrate significant anti-inflammatory effects that occur partly independent of the magnitude of weight loss. In the STEP-HFpEF program (STEP-HFpEF and STEP-HFpEF DM randomized controlled trials), semaglutide significantly reduced C-reactive protein (CRP) levels, improved heart failure symptoms and physical limitations, and in pooled analyses reduced worsening heart failure events in patients with established heart failure with preserved ejection fraction (HFpEF). However, stating that GLP-1 drugs 'prevent HFpEF' and 'should work well in people who aren't even obese' overstates the evidence. The pivotal clinical trials specifically enrolled individuals with overweight or obesity (e.g., BMI ≥30 kg/m²), and evaluated the management of established obesity-related HFpEF and secondary worsening events rather than primary prevention in non-obese populations.

0:54:07Eric Topoloverstatedlow

AI analysis of retinal photographs can predict the onset of Alzheimer's disease 5 to 7 years in advance.

"So I have a picture of the retina and you do AI on it, and it tells you when you're going to have Alzheimer's, if you're going to have Alzheimer's 5 to 7 years in advance." (said at 0:54:07)

While research using deep learning on retinal imaging (such as fundus photography and optical coherence tomography) shows that retinal microvascular and structural features are associated with neurodegenerative risk factors and preclinical changes years before diagnosis, artificial intelligence cannot deterministically predict whether or precisely when an individual will develop Alzheimer's disease 5 to 7 years in advance. Existing deep learning models are investigational tools evaluated in large research cohorts (such as the UK Biobank) that demonstrate statistical risk associations and classification capabilities, but they are not validated clinical diagnostic tools that pinpoint future Alzheimer's onset.

1:00:15Eric Topoloverstatedmoderate

Failure to lower LDL cholesterol below 100 mg/dL or 70 mg/dL is associated with an increased risk of developing dementia.

"and Alzheimer's, as you know, accounts for 70% of dementia—that if you don't have the LDL lowered to, let's say, less than 100, less than 70, you're going to be at higher risk for dementia." (said at 1:00:15)

While observational studies and meta-analyses indicate that elevated midlife LDL cholesterol (e.g., >121 mg/dL) is associated with an increased risk of Alzheimer's disease, there is no evidence establishing that failing to achieve specific cardiovascular targets (<100 mg/dL or <70 mg/dL) increases dementia risk. Furthermore, an individual participant data meta-analysis of over 21,000 older adults found no significant association between LDL cholesterol levels and incident dementia or cognitive decline, and meta-analyses of randomized trials of intensive LDL-lowering therapies (such as PCSK9 inhibitors) have not shown a statistically significant reduction in the risk of dementia or Alzheimer's disease.

1:10:54Eric Topoloverstatedlow

Personalized neoantigen vaccines have achieved cures in patients with treatment-refractory pancreatic cancer and renal cell carcinoma.

"personalized neoantigen vaccines to cure pancreatic cancer, to cure renal cell carcinoma, intractable, that is people that failed everything else." (said at 1:10:54)

Personalized neoantigen vaccines have shown promising immunogenicity and improved recurrence-free survival in early phase I clinical trials, but they have not been shown to 'cure' pancreatic cancer or renal cell carcinoma (RCC), nor were the landmark trials conducted in patients with intractable disease who had failed all other therapies. In a phase I trial for pancreatic ductal adenocarcinoma (PDAC), an individualized mRNA neoantigen vaccine (autogene cevumeran) was administered as adjuvant therapy following complete surgical resection alongside chemotherapy and immunotherapy; 8 of 16 patients developed neoantigen-specific T-cell responses and experienced delayed disease recurrence, not confirmed cures. Similarly, a phase I trial of a neoantigen vaccine in RCC enrolled 9 patients with fully resected, high-risk disease in the adjuvant setting rather than treatment-refractory disease. These phase I trials demonstrate biological activity and preliminary feasibility in post-surgical settings, but neither establishes curative efficacy nor applies to intractable, end-stage disease.

  • partial: Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. (Nature 2023) · cited 1351x in the literature
    "Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA-lipoplex nanoparticles, we synthesized mRNA neoantigen vaccines in real time from surgically resected PDAC tumours. After surgery, we sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), autogene cevumeran (a maximum of 20 neoantigens per patient) and a modified version of a four-drug chemotherapy regimen (mFOLFIRINOX)... At 18-month median follow-up, patients with vaccine-expanded T cells (responders) had a longer median recurrence-free survival (not reached) compared with patients without vaccine-expanded T cells (non-responders; 13.4 months, P = 0.003)." (abstract, results, passage verified)
    pubmedfull study (doi)
  • partial: A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. (Nature 2025) · cited 192x in the literature
    "Here we conducted a phase I trial (ClinicalTrials.gov identifier NCT02950766) to test a neoantigen-targeting PCV in patients with high-risk, fully resected clear cell renal cell carcinoma (RCC; stage III or IV) with or without ipilimumab administered adjacent to the vaccine. At a median follow-up of 40.2 months after surgery, none of the 9 participants enrolled in the study had a recurrence of RCC." (abstract, results, passage verified)
    pubmedfull study (doi)
3

Needs context

0:26:43Eric Topolneeds contexthigh

GLP-1 receptor agonist medications are currently being evaluated in major Alzheimer's disease clinical trials in non-overweight and non-obese populations.

"now we have the GLP-1 drugs like Ozempic, Mounjaro that are being tested in big Alzheimer's trials in thin people. You know, these are not obese or overweight; these are thin people, and because they have such potency of reducing brain inflammation" (said at 0:26:43)

Major Phase 3 clinical trials (evoke and evoke+) evaluated the GLP-1 receptor agonist semaglutide in large populations of patients with early-stage symptomatic Alzheimer's disease, enrolling participants based on amyloid positivity and cognitive impairment rather than elevated BMI or diabetes, thus including non-obese and normal-weight individuals. However, the Phase 3 trial results demonstrated that semaglutide did not slow clinical cognitive progression compared to placebo.

0:50:45Mark Hyman (host)needs contextmoderate

In an American Journal of Cardiology study, 39% of the population had blood lead levels over 2 µg/dL, and those individuals had an increased risk of heart attack and stroke comparable to or higher than elevated cholesterol.

"I remember reading a paper, I think it was the American Journal of Cardiology years ago, where they looked at anybody who had lead levels over two, which is considered normal because level in the reference range is 1 to 10... That their risk of having a heart attack was higher or as high as those who had elevated cholesterol and an increased risk of strokes, and it was a big risk factor. And it was 39% of the population that had a lead level over two" (said at 0:50:45)

The speaker conflates specific statistics and misnames the journal, but correctly reflects the general findings of landmark prospective epidemiological research on low-level lead exposure and cardiovascular mortality. In an analysis of 14,289 adults from the NHANES III cohort followed for nearly 20 years (published in The Lancet Public Health, not the American Journal of Cardiology), geometric mean blood lead was 2.71 µg/dL. Increasing blood lead from 1.0 to 6.7 µg/dL was associated with a more than two-fold increase in ischemic heart disease mortality (HR 2.08, 95% CI 1.52–2.85) and a 70% increase in cardiovascular mortality (HR 1.70, 95% CI 1.30–2.22). The population attributable fraction for ischemic heart disease mortality was estimated at 37.4% (roughly 185,000 deaths annually in the US), a disease burden comparable to major traditional risk factors such as smoking and dyslipidemia. The speaker appears to have conflated this attributable fraction (37.4%) or the proportion of cardiovascular deaths in the cohort (38%) with the prevalence of exposure.

  • context: Low-level lead exposure and mortality in US adults: a population-based cohort study. (The Lancet. Public health 2018) · cited 620x in the literature
    "An increase in the concentration of lead in blood from 1·0 μg/dL to 6·7 μg/dL (0·048 μmol/L to 0·324 μmol/L), which represents the tenth to 90th percentiles, was associated with all-cause mortality (hazard ratio 1·37, 95% CI 1·17-1·60), cardiovascular disease mortality (1·70, 1·30-2·22), and ischaemic heart disease mortality (2·08, 1·52-2·85). The population attributable fraction of the concentration of lead in blood for all-cause mortality was 18·0% (95% CI 10·9-26·1), which is equivalent to 412 000 deaths annually. Respective fractions were 28·7% (15·5-39·5) for cardiovascular disease mortality and 37·4% (23·4-48·6) for ischaemic heart disease mortality, which correspond to 256 000 deaths a year from cardiovascular disease and 185 000 deaths a year from ischaemic heart disease." (abstract, results, passage verified)
    pubmedfull study (doi)
1:21:40Mark Hyman (host)needs contexthigh

A Swedish trial of over 100,000 women demonstrated that AI-assisted mammography screening detected 25% more cancers than radiologists alone with no increase in false positives.

"100,000-plus women in Sweden, the AI picked up 25% more cancers compared to radiologists alone, you know, significant cancers, and no increase in false positives." (said at 1:21:40)

The statement references the Swedish Mammography Screening with Artificial Intelligence (MASAI) randomized controlled trial published in The Lancet Oncology, but contains minor numerical discrepancies. In the published interim safety analysis of 80,033 women (analyzing 39,996 in the AI-supported group and 40,024 in the standard double reading group), AI-supported screening detected 20% more cancers than standard double reading (244 vs 203 screen-detected cancers; detection rate 6.1 vs 5.1 per 1,000 participants; ratio 1.2, 95% CI 1.0-1.5, p=0.052), rather than 25%. The false-positive rate was identical in both groups at 1.5% (95% CI 1.4-1.7%). Most detected cancers in both groups were invasive (75% in the AI group vs 81% in the control group).

  • supports: Artificial intelligence-supported screen reading versus standard double reading in the Mam… (The Lancet. Oncology 2023) · cited 555x in the literature
    "Between April 12, 2021, and July 28, 2022, 80 033 women were randomly assigned to AI-supported screening (n=40 003) or double reading without AI (n=40 030)... AI-supported screening among 39 996 participants resulted in 244 screen-detected cancers... Standard screening among 40 024 participants resulted in 203 screen-detected cancers... Cancer detection rates were 6·1 (95% CI 5·4-6·9) per 1000 screened participants in the intervention group, above the lowest acceptable limit for safety, and 5·1 (4·4-5·8) per 1000 in the control group-a ratio of 1·2 (95% CI 1·0-1·5; p=0·052)... The false positive rate was 1·5% (95% CI 1·4-1·7) in both groups." (abstract, results)
    pubmedfull study (doi)
36

Supported by research

0:00:27Eric Topolsupportedmoderate

Scientific data demonstrates that social isolation is an independent risk factor for neurodegenerative disease, cardiovascular disease, and cancer.

"There's so much data to show that that social isolation is a risk factor for neurodegenerative and cardiovascular and even cancer." (said at 0:00:27)

Large-scale prospective cohort studies and meta-analyses support the claim that social isolation is an independent risk factor associated with increased risks of neurodegenerative disease (such as dementia), cardiovascular disease, and cancer mortality. A 2023 meta-analysis of 90 prospective cohort studies comprising over 2.2 million individuals found that social isolation was significantly associated with elevated risks of cardiovascular disease mortality (pooled effect size 1.34) and cancer mortality (pooled effect size 1.24). Furthermore, a prospective cohort study of 462,619 UK Biobank participants demonstrated that social isolation independently increased the risk of incident all-cause dementia by 26% (hazard ratio 1.26) after adjusting for extensive demographic, biological, and socioeconomic covariates.

0:03:04Eric Topolsupportedmoderate

Whole-genome sequencing of 1,400 individuals in the Welderly study (average age near 90 with no chronic illnesses) revealed almost no common protective genetic underpinnings.

"So it was called the Welderly study and it took seven years to find 1,400 people who were average age near 90 and up to 102 who had never had a chronic illness uh age-related or otherwise... we did whole genome sequencing on all of them and surprisingly we thought we'd find as you said all these genetic underpinnings and we found almost nothing." (said at 0:03:04)

Whole-genome sequencing of the Welderly cohort (healthy elderly individuals aged 80 and older who had never developed chronic diseases) demonstrated that healthy aging was not driven by distinct common longevity variants or an absence of rare pathogenic variants. While the investigators found modest reductions in polygenic susceptibility to Alzheimer's disease and coronary artery disease alongside suggestive loci related to cognitive preservation, the sequencing did not uncover definitive master protective genetic variants explaining their exceptional disease-free survival.

  • supports: Whole-Genome Sequencing of a Healthy Aging Cohort. (Cell 2016) · cited 250x in the literature
    "In contrast with studies of exceptional longevity, usually focused on centenarians, healthy aging is not associated with known longevity variants, but is associated with reduced genetic susceptibility to Alzheimer and coronary artery disease. Additionally, healthy aging is not associated with a decreased rate of rare pathogenic variants, potentially indicating the presence of disease-resistance factors." (abstract, results, passage verified)
    pubmedfull study (doi)
0:05:07Eric Topolsupportedlow

Multiple studies show that high polygenic disease risk can be neutralized by adopting healthy lifestyle factors.

"there are several studies I review in the book of polygenic risk uh and how that's neutralized by lifestyle factors." (said at 0:05:07)

Multiple large prospective cohort studies demonstrate that adhering to a healthy lifestyle (such as not smoking, regular physical activity, a healthy diet, and maintaining a healthy body weight) substantially offsets or attenuates the elevated risk conferred by high polygenic risk scores across multiple conditions, including coronary artery disease, stroke, and dementia. For example, a landmark study of over 55,000 participants published in The New England Journal of Medicine found that a favorable lifestyle was associated with a ~46–50% lower relative risk of coronary events among individuals in the highest quintile of genetic risk. Similar independent protective associations have been demonstrated for dementia and stroke in the UK Biobank. Under GRADE criteria, certainty is graded as low because the underlying evidence is observational.

0:07:40Eric Topolsupportedmoderate

Proteomic analysis using up to 11,000 plasma proteins can determine eight distinct organ aging clocks, including brain, heart, liver, kidney, and immune system.

"these protein or proteomic scores where you take up to 11,000 plasma proteins and you get eight organ clocks including the immune system. So brain, heart, liver, kidney." (said at 0:07:40)

Large-scale plasma proteomic studies using high-throughput platforms (such as SomaScan assays measuring thousands of plasma proteins, up to 11,000 targets) have developed and validated organ-specific proteomic biological aging clocks. These models assess distinct biological age gaps across major organs and systems, including the brain, heart, liver, kidney, and immune system, and have demonstrated predictive validity for organ-specific disease onset and mortality in large human cohorts.

0:08:10Eric Topolsupportedhigh

The UK Biobank is measuring proteomic profiles across 500,000 participants at a cost of approximately $50 per person, having already profiled over 50,000 individuals.

"and the biobank, UK Biobank is doing it for $50 for in 500,000 people. They've already done it in 50-some thousand." (said at 0:08:10)

The published record confirms that the UK Biobank Pharma Proteomics Project characterized plasma proteomic profiles for an initial phase of 54,219 participants ("50-some thousand"), as part of ongoing efforts to scale proteomic profiling across the broader UK Biobank cohort of 500,000 individuals.

0:11:48Eric Topolsupportedmoderate

Cardiovascular disease is 80% to 90% preventable through lifestyle, while cancer and neurodegenerative diseases are 40% to 50% preventable through lifestyle.

"cardiovascular is the most preventable of these three diseases. Um, 80 90%. Uh, our colleagues, uh, former colleagues from Cleveland Clinic came out with that's 90%, others 80%. But then cancer and neurodegenerative are 40 50% preventable through lifestyle." (said at 0:11:48)

Large-scale epidemiological studies and major consensus reports support these estimates. In cardiovascular disease, the landmark global INTERHEART study found that nine modifiable lifestyle and cardiometabolic risk factors accounted for 90% of the population attributable risk of myocardial infarction in men and 94% in women, with other major cardiovascular bodies commonly citing 80% to 90% preventability. For cancer, epidemiological analyses consistently estimate that 40% to 50% of incident cancer cases are attributable to modifiable lifestyle and environmental risk factors (such as tobacco use, diet, excess weight, alcohol, and physical inactivity). Similarly, major consensus bodies such as the Lancet Commission on dementia estimate that approximately 40% to 45% of dementia cases worldwide are attributable to modifiable lifestyle and health risk factors across the lifespan.

0:28:55Eric Topolsupportedhigh

The Alzheimer's Association diagnostic criteria categorize individuals with elevated plasma p-tau217 as having stage 1 Alzheimer's disease.

"And the American Alzheimer's Association, which I think has some problems, they're labeling people with p-tau217 as stage one Alzheimer's if it's elevated." (said at 0:28:55)

The revised criteria from the Alzheimer's Association Workgroup (Jack et al., 2024) establish a biological definition of Alzheimer's disease (AD) wherein disease onset occurs while individuals are asymptomatic. Under this framework, Core 1 biomarkers—specifically including accurate plasma biomarkers such as phosphorylated tau 217 (p-tau217)—are sufficient to establish a biological diagnosis of AD. Under the clinical staging framework, individuals who test positive for AD biomarkers but remain asymptomatic/cognitively unimpaired are categorized as having Stage 1 Alzheimer's disease.

0:10:12Eric Topolsupportedmoderate

The development of the three major categories of age-related diseases—most cancers, cardiovascular disease, and neurodegenerative disease—takes more than 20 years before clinical manifestation.

"The three major age-related diseases uh take more than 20 years. Uh cancer for almost all cancers, uh cardiovascular and certainly Alzheimer's neurodegenerative they take more than 20 years" (said at 0:10:12)

Scientific consensus across geroscience, oncology, cardiology, and neurology confirms that the preclinical development of the major chronic age-related diseases typically spans decades before clinical diagnosis. For neurodegenerative diseases such as Alzheimer's disease, biomarker and neuropathological studies demonstrate that pathological cascades (including amyloid-beta deposition and tau pathology) begin 20 or more years prior to symptom onset. Similarly, cardiovascular disease develops via atherosclerosis beginning in early life as fatty streaks that evolve over decades before resulting in acute events, and genomic/evolutionary modeling of common adult solid cancers indicates that initial driver mutations often precede clinical tumor manifestation by 15 to 30 years.

0:18:28Eric Topolsupportedvery low

Researchers are actively using gene editing techniques to convert the APOE4 allele into APOE2 in animal models.

"there's a whole chapter in the book where people are editing APO turning APOE4 into APOE2 right now. I mean, ... In animals and you know, the idea of to do this in people that may happen someday" (said at 0:18:28)

Preclinical researchers are actively investigating genetic and gene-editing strategies to convert the high-risk APOE4 allele into protective or lower-risk variants such as APOE2 and APOE3 in animal models. For example, mouse models engineered for inducible allelic switching from APOE4 to APOE2 have demonstrated improvements in cerebral lipid profiles, reduction of amyloid pathology, and reversal of cognitive deficits. Additionally, CRISPR- and prime-editing platforms are being actively tested in vivo in humanized APOE4 mouse models to convert APOE4 toward lower-risk alleles.

0:33:05Mark Hyman (host)supportedhigh

Daily protein intake beyond 1.5 to 1.6 grams per kilogram of body weight does not yield additional increases in muscle mass in clinical studies.

"And it's not going to increase their muscle mass when you go past good studies, 1.5, 1.6 per kilogram." (said at 0:33:05)

A landmark systematic review, meta-analysis, and meta-regression of 49 randomized controlled trials with 1,863 participants undergoing resistance exercise training found that dietary protein supplementation enhanced gains in fat-free mass up to a plateau. Two-phase breakpoint analysis demonstrated that protein intakes exceeding approximately 1.62 g/kg/day provided no further resistance training-induced gains in fat-free mass or muscle size.

0:33:40Mark Hyman (host)supportedmoderate

In a 30-year follow-up study of 105,000 people, only 9% reached elderly age past 70 in healthy status, and those 9% predominantly consumed plant-based foods, a Mediterranean diet, and small amounts of red meat.

"And you're familiar with this recent study of 105,000 people followed 30 years, and only 9% of them only 9% got to the elderly state past age 70. And those 9%, what did they eat? They mainly ate plant-based foods, Mediterranean diet, some but small amounts of red meat" (said at 0:33:40)

A 2025 prospective cohort study published in Nature Medicine analyzed 105,015 participants from the Nurses' Health Study and the Health Professionals Follow-Up Study followed for up to 30 years (1986–2016). The researchers found that only 9,771 participants (9.3%) achieved healthy aging, defined as surviving to age 70 or older free of major chronic diseases and with intact cognitive, physical, and mental function. Greater adherence to healthy dietary patterns (including the Mediterranean diet, Alternative Healthy Eating Index, and healthful plant-based diets rich in fruits, vegetables, whole grains, nuts, legumes, and unsaturated fats, alongside minimal intake of red and processed meats) was significantly associated with achieving healthy aging.

  • supports: Optimal dietary patterns for healthy aging. (Nature medicine 2025) · cited 196x in the literature
    "Here, using longitudinal questionnaire data from the Nurses' Health Study (1986-2016) and the Health Professionals Follow-Up Study (1986-2016), we examined the association of long-term adherence to eight dietary patterns and ultraprocessed food consumption with healthy aging, as assessed according to measures of cognitive, physical and mental health, as well as living to 70 years of age free of chronic diseases. After up to 30 years of follow-up, 9,771 (9.3%) of 105,015 participants (66% women, mean age = 53 years (s.d. = 8)) achieved healthy aging... Higher intakes of fruits, vegetables, whole grains, unsaturated fats, nuts, legumes and low-fat dairy products were linked to greater odds of healthy aging, whereas higher intakes of trans fats, sodium, sugary beverages and red or processed meats (or both) were inversely associated." (abstract, results, passage verified)
    pubmedfull study (doi)
0:39:20Eric Topolsupportedmoderate

Slow-wave deep sleep is the specific sleep stage during which the brain clears toxic waste metabolites.

"the link between the deep sleep, which is when we get rid of the toxic waste metabolites in our brain, that's the time." (said at 0:39:20)

Mechanistic animal and human physiological studies demonstrate that sleep—particularly non-rapid eye movement (NREM) slow-wave deep sleep—substantially enhances the clearance of toxic metabolic waste products (such as amyloid-beta and tau) from the central nervous system via the glymphatic system. Preclinical work showed a dramatic expansion of the interstitial space and increased convective cerebrospinal fluid (CSF)-interstitial fluid exchange during sleep, and human neuroimaging confirmed that electrophysiological slow waves in NREM sleep drive large coupled waves of CSF flow responsible for waste clearance.

0:39:35Mark Hyman (host)supportedvery low

Zolpidem (Ambien) impairs brain waste clearance and increases metabolite waste retention in the brain.

"And what's interesting is that they backfire. Not only do they not get rid of the waste, but they actually increase—Ambien especially been noted to increase the waste that stay in the brain." (said at 0:39:35)

Preclinical rodent research supports the claim that zolpidem (Ambien) impairs sleep-dependent glymphatic flow. A 2025 study in Cell demonstrated that natural glymphatic clearance during NREM sleep is driven by synchronized oscillations in norepinephrine and slow vasomotion; administration of zolpidem suppressed these norepinephrine oscillations and significantly reduced glymphatic flow. Because these findings are derived from animal models and mechanistic neuroimaging rather than clinical outcome trials in humans, the certainty of the evidence is very low.

0:43:08Mark Hyman (host)supportedmoderate

A clinical trial in elderly individuals found that intermittent dosing of rapamycin improved immune function and vaccine response, whereas continuous dosing did not.

"there was one trial I saw that was on elderly and they found that if it was given intermittently, it actually improved their response to vaccines and and actually helped their immune system function better, whereas continuous dosing didn't." (said at 0:43:08)

A randomized, placebo-controlled phase 2a clinical trial in 218 elderly volunteers evaluated the mTOR inhibitor RAD001 (an analog of rapamycin) given in different regimens (0.5 mg daily, 5 mg weekly, 20 mg weekly, or placebo) for 6 weeks prior to influenza vaccination. The study found that low-dose mTOR inhibition—particularly weekly intermittent dosing—enhanced the response to influenza vaccination by approximately 20% and decreased the proportion of PD-1-positive CD4 and CD8 T cells, whereas higher continuous dosing is known to cause generalized immunosuppression.

0:44:42Mark Hyman (host)supportedhigh

Metformin inhibits mitochondrial complex I and blunts muscle hypertrophy gains when combined with progressive resistance training compared to resistance training alone.

"But it does inhibit mitochondrial complex I, which worries me because with progressive resistance training compared to placebo with and without metformin, if you did strength training with metformin, you didn't get the same response to building muscle" (said at 0:44:42)

Metformin is a well-established mild inhibitor of mitochondrial complex I, and randomized clinical trial evidence demonstrates that it blunts muscle hypertrophy gains during progressive resistance training (PRT). In the double-blind, placebo-controlled MASTERS trial (n=94 healthy adults aged ≥65 years undergoing 14 weeks of supervised PRT), participants receiving placebo gained significantly more lean body mass, thigh muscle mass, and CT-measured thigh muscle cross-sectional area compared to those receiving 1,700 mg/day of metformin.

0:46:12Eric Topolsupportedmoderate

A multicenter Italian study found microplastics and nanoplastics in carotid artery plaques in over 60% of surgical patients.

"The big study from Italy, multiple centers, where they took the carotid artery plaque at the time of surgery and they looked to see if there was plastics, microplastics, nanoplastics in the artery plaque, and they found it in over 60% of people." (said at 0:46:12)

A prospective, multicenter Italian study published in the New England Journal of Medicine (Marfella et al., 2024) examined carotid artery plaque specimens retrieved during carotid endarterectomy. Among 257 patients with complete follow-up, polyethylene microplastics and nanoplastics were detected in 150 patients (58.4%), and polyvinyl chloride was detected in 31 patients (12.1%). Although the speaker slightly rounded up from 58.4% to 'over 60%', the core factual description of the multicenter surgical study and the detection rate is accurate.

0:46:41Eric Topolsupportedlow

Patients with microplastics detected in carotid artery plaques had a four- to five-fold increased risk of myocardial infarction, stroke, and all-cause mortality compared to those without plastics.

"And what was even worse is the people who had the plastics followed versus those who didn't have plastics in their in their plaque had a four to fivefold increase of heart attacks, strokes, and death compared to those without the plastic" (said at 0:46:41)

A prospective multicenter observational study published in The New England Journal of Medicine (Marfella et al., 2024) evaluated 257 patients undergoing carotid endarterectomy followed for a mean of 34 months. Patients with detectable microplastics and nanoplastics in their carotid atheromas had a 4.53-fold higher risk of experiencing the composite primary endpoint of myocardial infarction, stroke, or all-cause mortality compared to those without detectable plastics (hazard ratio 4.53, 95% CI 2.00 to 10.27, P < 0.001). As an observational cohort study, certainty is rated as low according to GRADE criteria.

0:51:47Eric Topolsupportedhigh

Cardiovascular disease is the leading cause of death worldwide and the leading cause of death among women.

"it's still the number one killer around the world, not just here. And it's still the number one killer in women who, you know, they think that it's breast cancer." (said at 0:51:47)

Global epidemiological surveillance data confirm that cardiovascular disease (CVD) is the leading cause of mortality globally as well as the leading cause of death among women worldwide. Comprehensive findings from the Global Burden of Disease Study 2023 estimated 19.2 million CVD deaths globally in 2023, making CVD the foremost cause of both mortality and disability-adjusted life years worldwide. Furthermore, the Lancet Women and Cardiovascular Disease Commission confirms that CVD remains the leading cause of death among women globally, accounting for substantially more female deaths than breast cancer or any other individual malignancy.

0:54:20Eric Topolsupportedmoderate

AI analysis of retinal imaging can assess risk of coronary artery disease, stroke, and predict coronary artery calcium score.

"The retina also tells if you're going to have heart disease or a stroke in advance. It will even tell your calcium score of your heart arteries through your retina." (said at 0:54:20)

Deep-learning models applied to retinal fundus photographs have been developed and validated to predict coronary artery calcium (CAC) score categories and forecast cardiovascular disease (CVD) events, including stroke and coronary disease. In a study of 216,152 retinal photographs across cohorts from South Korea, Singapore, and the UK Biobank, a deep-learning algorithm predicting CAC (RetiCAC) achieved an AUROC of 0.742 for CAC presence and prognostic concordance comparable to CT-measured CAC scoring (c-index 0.71). Similarly, deep learning algorithms achieved an AUROC of 83.2% for discriminating no CAC from high CAC scores (>100) using bilateral fundus photographs.

0:55:45Eric Topolsupportedmoderate

Pericoronary arterial inflammation detected by CT AI imaging without artery narrowing is associated with a 15-fold increased risk of myocardial infarction.

"This is a University of Oxford spinout. I think it's called Caristo. They're going to have that available soon. And I went through the data in the book. I mean, they've had multiple papers, but it's striking. If you have inflammation without a narrowing, you could have a 15-fold risk of a heart attack." (said at 0:55:45)

Evidence from large prospective and longitudinal cohort studies led by University of Oxford researchers (and commercialized via the spinout Caristo Diagnostics) supports the claim. In the ORFAN study of over 40,000 patients undergoing coronary computed tomography angiography (CCTA), perivascular fat attenuation index (FAI) Score—an AI-enabled imaging biomarker of pericoronary inflammation—predicted major adverse cardiac events (MACE, including myocardial infarction) and cardiac mortality independently of traditional risk factors and the presence of obstructive coronary artery disease. Specifically, individuals with high inflammation (top vs. bottom quartile FAI Score across all three coronary vessels) had a 12.6-fold higher risk of MACE (HR 12.6, 95% CI 8.5–18.6) and a nearly 30-fold higher risk of cardiac mortality (HR 29.8, 95% CI 13.9–63.9), demonstrating substantial risk even in the absence of obstructive arterial narrowing.

0:57:26Eric Topolsupportedmoderate

Adherence to key healthy lifestyle factors extends healthy lifespan by 7 to 10 years free of major age-related chronic diseases.

"In the book, I found all these studies that I was really struck by that are recent that showed that if we practice the lifestyle factors that we've been reviewing with the details that we discussed, that gets us 7 to 10 years of healthy aging without one of these age-related diseases." (said at 0:57:26)

Large prospective cohort analyses directly support this statement. In a major prospective study analyzing data from the Nurses' Health Study (n=73,196) and the Health Professionals Follow-Up Study (n=38,366), adopting 4 to 5 low-risk lifestyle factors (never smoking, healthy weight/BMI, regular physical activity, moderate alcohol intake, and high diet quality) was associated with a 10.7-year increase in disease-free life expectancy (free of diabetes, cardiovascular disease, and cancer) at age 50 among women (34.4 vs. 23.7 years) and a 7.6-year increase among men (31.1 vs. 23.5 years) compared with individuals adhering to zero low-risk lifestyle factors.

1:00:47Eric Topolsupportedhigh

Taking high-potency statin medications increases the risk of developing type 2 diabetes.

"When I wrote an op-ed in the New York Times like a decade ago and I called out the diabetes from statins, okay, because if you take a very potent statin, you have a higher risk of developing type 2 diabetes, right?" (said at 1:00:47)

High-quality randomized trial meta-analyses confirm that statin therapy—and higher-intensity or more potent statin regimens in particular—is associated with a modest but statistically significant increased risk of developing type 2 diabetes. A meta-analysis of five large randomized controlled trials (32,752 participants) comparing intensive-dose statin therapy to moderate-dose therapy found an increased risk of new-onset diabetes in the intensive-dose group (odds ratio 1.12, 95% CI 1.04–1.22), representing roughly 2.0 additional cases of diabetes per 1,000 patient-years.

0:53:38Eric Topolsupportedhigh

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all heart failure cases.

"and we've seen how that can prevent heart—preserve ejection fraction heart failure, which is half of all heart failure, right?" (said at 0:53:38)

Large-scale epidemiological studies and registries consistently indicate that heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% (and in some aging populations, more than half) of all heart failure cases.

1:00:15Eric Topolsupportedhigh

Alzheimer's disease accounts for approximately 70% of all dementia cases.

"and Alzheimer's, as you know, accounts for 70% of dementia" (said at 1:00:15)

Epidemiological data and major health organizations (including the World Health Organization and Alzheimer's Association) consistently report that Alzheimer's disease is the most common etiology of dementia, accounting for approximately 60% to 70% of all cases worldwide.

1:01:18Eric Topolsupportedhigh

High doses of potent statins like rosuvastatin and atorvastatin increase the risk of developing type 2 diabetes and elevating blood glucose levels.

"over the years, we've seen many more reports about the potent statins, high doses where you get a higher risk... if we're going to lower LDL and pull out all the stops and high doses of rosuvastatin (Crestor) or atorvastatin (Lipitor), that could also raise the risk of that person developing type 2 diabetes." (said at 1:01:18)

Extensive evidence from large randomized controlled trials and meta-analyses demonstrates that statin therapy, particularly intensive- or high-dose therapy with potent statins such as atorvastatin and rosuvastatin, is associated with a statistically significant, dose-dependent increase in the risk of incident (new-onset) type 2 diabetes.

1:02:04Mark Hyman (host)supportedmoderate

Mitochondrial damage is observed on muscle biopsies of patients taking statins even in the absence of muscle pain or elevated muscle enzymes.

"some of the data I've seen that even in people without muscle pain, even without elevated muscle enzymes, that there's mitochondrial damage on muscle biopsies." (said at 1:02:04)

Muscle biopsy studies in humans demonstrate that statin therapy can cause subclinical mitochondrial alterations (such as reduced citrate synthase activity, repression of mitochondrial gene expression pathways, and subtle reductions in mitochondrial content or oxidative parameters) even in patients without muscle symptoms (myalgia) and without elevations in serum creatine kinase (CK). Small clinical trials and cross-sectional studies examining asymptomatic statin users have reported these subclinical metabolic perturbations in skeletal muscle tissue.

1:02:34Eric Topolsupportedhigh

PCSK9 inhibitor injectable drugs lower LDL effectively and are not associated with an increased risk of diabetes.

"the PCSK9 injectable drugs are a winner because they're potent and they have not been associated with diabetes, which is really interesting." (said at 1:02:34)

Large-scale systematic reviews and meta-analyses of randomized controlled trials (including major outcome trials such as FOURIER and ODYSSEY OUTCOMES) demonstrate that injectable PCSK9 inhibitors (such as alirocumab and evolocumab) markedly reduce LDL-C without significantly increasing the risk of new-onset diabetes mellitus compared with placebo or standard care.

1:07:41Eric Topolsupportedhigh

Approximately 12% of women will develop breast cancer in their lifetime, while 88% will not.

"Only 12% of women in their lifetime will ever have breast cancer. 88% will never develop breast cancer" (said at 1:07:41)

Population-based cancer registry data consistently demonstrate that the cumulative lifetime risk for a woman to develop invasive breast cancer is approximately 1 in 8 (roughly 12% to 13%), meaning approximately 87% to 88% of women will never develop the disease.

1:08:51Eric Topolsupportedmoderate

Nearly 400,000 individuals have taken the Galleri multi-cancer early detection liquid biopsy test.

"The one that's used the most is Galleri of GRAIL. And almost 400,000 people have had that test." (said at 1:08:51)

Published real-world evidence and clinical trial data confirm substantial commercial and clinical use of GRAIL's Galleri multi-cancer early detection (MCED) test. Peer-reviewed real-world registries have documented more than 110,000 commercial tests in single cohorts (such as an analysis of 111,080 individuals published in 2025), which, combined with large-scale clinical trials (including the NHS-Galleri trial of ~140,000 participants) and continued commercial adoption, aligns with estimates approaching 400,000 tests administered.

1:08:51Eric Topolsupportedmoderate

When used in healthy adults age 50 and older, the detection rate of early-stage cancer with the Galleri test is approximately 2 per 1,000 people.

"The yield for that test is very low, and most of it is already late stage. Two out of a thousand you might pick up an early cancer." (said at 1:08:51)

In the prospective PATHFINDER study evaluating the Galleri multi-cancer early detection (MCED) blood test in 6,621 asymptomatic adults aged 50 years or older (PMID: 37805216), a cancer signal was detected in 92 participants (1.4%), leading to a confirmed cancer diagnosis (true positives) in 35 participants (~5.3 per 1,000 individuals screened). Approximately half of these confirmed cases were early-stage (Stage I–II) cancers, corresponding to an early-stage cancer detection rate of approximately 2 per 1,000 screened individuals.

1:10:54Eric Topolsupportedmoderate

A study using Danish and Veterans Affairs healthcare data showed that AI models analyzing electronic health records, including non-specific symptoms and normal-range laboratory trends, can identify elevated risk of pancreatic cancer earlier.

"We saw from the study that was done in Denmark and the VA for pancreatic cancer... they looked at a person's non-specific symptoms like, you know, abdominal symptoms for pancreatic cancer, and they saw ranges of liver function tests in the normal range, but trending in the wrong direction, right? So yeah, the AI picked up the higher risk" (said at 1:10:54)

A landmark 2023 study published in Nature Medicine applied deep learning models to electronic health record data from approximately 6 million patients in Denmark (Danish National Patient Registry) and 3 million patients in the United States (Veterans Affairs). The models analyzed sequences and trajectories of clinical disease codes—including early, non-specific abdominal symptoms and metabolic indicators—to predict pancreatic cancer occurrence up to 36 months before diagnosis (AUROC 0.88 in the Danish cohort; AUROC 0.78 upon retraining in the VA cohort), demonstrating that AI can identify individuals at substantially elevated risk for early surveillance.

  • supports: A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. (Nature medicine 2023) · cited 338x in the literature
    "In this study, we applied artificial intelligence methods to clinical data from 6 million patients (24,000 pancreatic cancer cases) in Denmark (Danish National Patient Registry (DNPR)) and from 3 million patients (3,900 cases) in the United States (US Veterans Affairs (US-VA)). We trained machine learning models on the sequence of disease codes in clinical histories and tested prediction of cancer occurrence within incremental time windows (CancerRiskNet). For cancer occurrence within 36 months, the performance of the best DNPR model has area under the receiver operating characteristic (AUROC) curve = 0.88 and decreases to AUROC (3m) = 0.83 when disease events within 3 months before cancer diagnosis are excluded from training..." (abstract, results, passage verified)
    pubmedfull study (doi)
1:16:28Eric Topolsupportedmoderate

Men carrying BRCA gene mutations have a higher risk of prostate cancer and other forms of cancer.

"BRCA2, we as men, you know, a lot of us are carrying a BRCA gene just because we don't have breast cancer, you know, that means we have a higher risk of prostate cancer ourselves and other forms of cancer." (said at 1:16:28)

Male carriers of BRCA pathogenic variants, particularly BRCA2 mutations, have well-documented elevated risks of developing prostate cancer and certain other malignancies, such as pancreatic and stomach cancers. In prospective and familial cohort studies, men with BRCA2 mutations demonstrate a 3- to 5-fold higher risk of prostate cancer (with even higher relative risks below age 65) and a significantly increased incidence of aggressive, clinically significant disease compared to non-carriers, alongside elevated risks for pancreatic and gastrointestinal cancers.

1:22:44Eric Topolsupportedmoderate

AI analysis of standard mammogram images can predict a woman's risk of developing breast cancer up to five years in advance.

"There's a big study that showed that if you have AI analysis of a regular mammogram, you can predict cancer in that woman five years ahead if they're going to develop cancer." (said at 1:22:44)

Large retrospective cohort studies have validated deep learning algorithms (such as Mirai and related mammography-based AI models) that analyze standard screening mammograms to estimate future breast cancer risk up to five years in advance. In multi-institutional datasets from the United States, Sweden, and Taiwan, these AI risk prediction models achieved concordance indices (C-indices) ranging from 0.76 to 0.81 for 1- to 5-year risk assessment, significantly outperforming traditional clinical models such as the Tyrer-Cuzick and Gail models.

1:24:19Eric Topolsupportedlow

CD19-targeted CAR-T cell therapy that depletes B cells has produced sustained remissions of severe autoimmune diseases like systemic lupus erythematosus and systemic sclerosis for over three years of follow-up.

"taking people with autoimmune diseases like lupus, systemic sclerosis, even multiple sclerosis, by giving them T cells, engineered T cells, CAR-T directed towards depleting their B cells, that when the B cells come back, they forgot that the person had disease... and for now three-some years of follow-up, they're cured of an autoimmune disease." (said at 1:24:19)

The spoken claim is supported by published clinical evidence evaluating CD19-targeted chimeric antigen receptor (CAR) T-cell therapy in patients with severe, treatment-refractory autoimmune diseases including systemic lupus erythematosus (SLE) and systemic sclerosis. Early trials, most notably a landmark study published in *The New England Journal of Medicine* by Müller et al. (2024), evaluated 15 patients with severe SLE, systemic sclerosis, or idiopathic inflammatory myositis following a single infusion of CD19 CAR T cells. Deep B-cell depletion was followed by B-cell repopulation, complete withdrawal of immunosuppressive drugs, and sustained drug-free remissions. Systematic synthesis of clinical studies demonstrates that sustained remissions across autoimmune rheumatic conditions extended up to 46 months (over three years) with follow-up. Because the underlying evidence consists of case series and non-randomized phase 1 trials without a control arm, certainty for the body of evidence is low despite the high magnitude of response observed.

  • supports: CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. (The New England journal of medicine 2024) · cited 1034x in the literature
    "We evaluated 15 patients with severe SLE (8 patients), idiopathic inflammatory myositis (3 patients), or systemic sclerosis (4 patients) who received a single infusion of CD19 chimeric antigen receptor (CAR) T cells after preconditioning with fludarabine and cyclophosphamide. Efficacy up to 2 years after CAR T-cell infusion was assessed... All the patients with SLE had DORIS remission, all the patients with idiopathic inflammatory myositis had an ACR-EULAR major clinical response, and all the patients with systemic sclerosis had a decrease in the score on the EUSTAR activity index. Immunosuppressive therapy was completely stopped in all the patients." (abstract, methods and results, passage verified)
    pubmedfull study (doi)
  • supports: CAR-T cell therapy for treatment-refractory rheumatic autoimmune diseases: a systematic re… (RMD open 2026) · cited 4x in the literature
    "12 studies encompassed 44 patients with severe treatment-refractory disease across six rheumatic conditions. Patients had extensive prior exposure (median 5 therapies), including conventional and biological agents. Cluster of Differentiation antigen 19 (CD19)-targeted constructs predominated (83% of studies)... Sustained drug-free remissions extended 6-46 months, accompanied by profound autoantibody reductions" (abstract, results, passage verified)
    pubmedfull study (doi)
1:20:53Eric Topolsupportedhigh

Researchers at Johns Hopkins led by Bert Vogelstein developed a blood-based cancer screening test that combines protein biomarkers and circulating gene variants.

"Right. So, that's a Johns Hopkins, Bert Vogelstein effort. And that's right. As you said, they combined some key proteins that have been established as markers with some gene variants and made a relatively inexpensive test, and that's one that certainly has a potential as well." (said at 1:20:53)

Researchers led by Bert Vogelstein, Nickolas Papadopoulos, Kenneth Kinzler, and colleagues at Johns Hopkins University developed CancerSEEK, a multi-analyte blood test designed to detect eight common cancer types. The assay combines the assessment of circulating protein biomarkers with the detection of mutations in cell-free DNA (circulating tumor DNA). In a landmark study evaluating 1,005 patients with nonmetastatic cancers and 812 healthy controls, the test achieved a median sensitivity of 70% across the eight cancer types with greater than 99% specificity.

1:34:07Eric Topolsupportedhigh

The criteria for the 'Welderly' is individuals aged 80 and older who have no major age-related diseases.

"I just want to get to whatever age and stay as long as I can to meet that kind of Welderly criteria of 80-plus and no age-related major diseases that we've been discussing." (said at 1:34:07)

The 'Welderly' study (conducted by the Scripps Research Institute) specifically defined its healthy aging cohort as individuals aged 80 years and older who have reached late life without developing major chronic or age-related diseases (such as cardiovascular disease, cancer, diabetes, or dementia) and without requiring chronic medical interventions.

  • supports: Whole-Genome Sequencing of a Healthy Aging Cohort. (Cell 2016) · cited 250x in the literature
    "Therefore, we pursued genome sequencing of a related phenotype-healthy aging-to understand the genetics of disease-free aging without medical intervention. In contrast with studies of exceptional longevity, usually focused on centenarians, healthy aging is not associated with known longevity variants, but is associated with reduced genetic susceptibility to Alzheimer and coronary artery disease." (abstract, passage verified)
    pubmedfull study (doi)
6

No source found (not proven false)

0:22:33Eric Topolunverifiedvery low

Approximately 20% to 25% of the human population carries the APOE4 allele.

"And if you are APOE4 I mean if you're a carrier that's 20 25% of us are carriers or you have a family history of Alzheimer's or both, you probably want to get a p-tau217" (said at 0:22:33)

No published record matching the claim that approximately 20% to 25% of the human population carries the APOE4 allele was located; this does not prove the claim false.

0:23:25Eric Topolunverifiedvery low

A randomized clinical study presented at the American Academy of Neurology showed that lifestyle intervention in individuals with elevated p-tau217 reduced p-tau biomarkers by up to 75%.

"And we've seen a randomized study presented here in San Diego at the Academy of Neurology annual meeting where they had these the people who are had p-tau217 elevated they they were randomly assigned to intervention with lifestyle and it came way down you know p-tau217, p-tau181, all these markers 75 up to 75% reduction" (said at 0:23:25)

No published record matching the claim of a randomized clinical study showing a lifestyle intervention reduced p-tau217 or other phosphorylated tau biomarkers by up to 75% was located; this does not prove the claim false. Conference abstracts presented at annual meetings may not yet be published as peer-reviewed articles.

0:31:15Eric Topolunverifiedvery low

In a 30-day self-experiment consuming ultra-processed food, Chris van Tulleken gained 20 pounds and showed widespread brain inflammation on imaging and elevated inflammatory biomarkers.

"He had a brain scan beforehand. He had all these inflam- inflammation markers beforehand. And in 30 days, kind of like Super Size Me, he tried to go as high as he could on ultra-processed food. By the time the 30 days was up, his brain was all inflamed. Every biomarker had gone through the ceiling of abnormality for inflammation. I mean, it was just 30 days of this bad diet. He gained 20 pounds." (said at 0:31:15)

No published record matching Chris van Tulleken's 30-day ultra-processed food self-experiment, purported 20-pound weight gain, brain inflammation imaging, or elevated inflammatory biomarkers was located; this does not prove the claim false. Although an informal n=1 dietary experiment was conducted for a television documentary and popularized in a non-academic book, no peer-reviewed scientific case report or trial documenting these specific findings exists in the published biomedical literature.

0:34:27Mark Hyman (host)unverifiedvery low

Sustaining a hip fracture carries a higher risk of death than receiving a cancer diagnosis.

"Frailty is the killer. I mean, hip fractures is a bigger risk for death than getting a diagnosis of cancer." (said at 0:34:27)

No published record matching the claim that sustaining a hip fracture carries a higher risk of death than receiving a cancer diagnosis was located; this does not prove the claim false.

1:16:28Eric Topolunverifiedvery low

Data from Iceland showed that carrying a BRCA2 mutation was associated with a difference of up to seven years in healthy aging/lifespan, predominantly due to cancer.

"I go through that BRCA2 story in some depth because of the Icelandic data where it made a difference of up to seven years of healthy aging, mainly because of cancer." (said at 1:16:28)

No published record matching the specific claim that Icelandic population data (e.g., from deCODE genetics) demonstrated an association between BRCA2 mutation carriage and up to a 7-year reduction in lifespan or healthy aging predominantly due to cancer was located; this does not prove the claim false.

1:16:28Eric Topolunverifiedvery low

A full whole-genome sequence can be performed at a cost of a couple hundred dollars.

"they can all be had in a sequence which costs a couple hundred dollars, a full whole-genome sequence." (said at 1:16:28)

No published record matching the claim that a full whole-genome sequence can be performed at a cost of a couple hundred dollars was located; this does not prove the claim false.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.